Introduction
============

TAFRO syndrome is a subset of idiopathic multicentric Castleman disease (iMCD) that is characterized by thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, organomegaly, and typically normal immunoglobulin levels ([@B1]). Although its onset may be acute or subacute, its etiology remains unknown. Patients with TAFRO syndrome exhibit systemic inflammation, polyclonal lymphoproliferation, and a wide spectrum of symptoms caused by a cytokine storm that often includes interleukin (IL)-6 and vascular endothelial growth factor (VEGF) ([@B2]).

VEGF is an angiogenic and mitogenic substance that appears to be active in vascular endothelial cells and plays an important role in tumor growth and the metastatic process ([@B3]). It is also a vascular permeability factor that induces rapid and reversible increases in vascular permeability ([@B3]). Relationships have been demonstrated between elevated VEGF levels and many pathological conditions ([@B4]-[@B6]), and a correlation has also been reported between elevated VEGF and TSH levels in patients with hypothyroidism ([@B4]). Although hypothyroidism is a common endocrine abnormality, its clinical significance in TAFRO syndrome remains unclear.

We investigated the thyroid function in detail to obtain a deeper understanding of its relationship with cytokines and the manifestations of thyroid abnormalities as well as their clinical significance in TAFRO syndrome. The present results indicate that even biochemical subclinical hypothyroidism causes severe clinical manifestations.

Materials and Methods
=====================

Between January 2010 and January 2018, 6 patients (4 men and 2 women) were diagnosed with TAFRO syndrome in our hospital. All patients presented with anasarca (pleural effusion and ascites), thrombocytopenia, anemia, renal dysfunction, ALP elevations, or low LDH levels. Other clinical findings included myelofibrosis, increased levels of megakaryocytes in bone marrow, and small or unclear lymphadenopathy on computed tomography (CT). All patients met the diagnostic criteria for TAFRO syndrome ([@B6]). Patient details are given in [Tables 1](#t001){ref-type="table"} and [2](#t002){ref-type="table"}.

The thyroid function was assessed in all patients. We evaluated the levels of thyroid-stimulating hormone (TSH) (normal range: 0.43-4.82 μIU/mL), free T3 (FT3) (normal range: 2.39-3.86 pg/mL), free T4 (FT4) (normal range: 0.87-1.72 ng/dL), antithyroid peroxidase antibody (TPO Ab) (normal range: \<9.4 IU/mL), and antithyroglobulin antibody levels (TG Ab) (normal range: \<54.6 IU/mL). The thyroid function was classified as euthyroidism (normal TSH and FT4 levels), subclinical hypothyroidism (elevated serum TSH levels in association with normal serum FT4 levels), and clinical hypothyroidism (a reduction in FT4 with increased serum TSH levels).

Plasma VEGF (normal range: \<38.3 pg/mL) and serum IL-6 (normal range: \<4.0 pg/mL) levels were measured by an enzyme-linked immunosorbent assay.

All patients provided their written informed consent to receive each regimen, and treatment was administered according to the principles of the Declaration of Helsinki. This study was approved by the institutional ethics committee.

Results
=======

All patients had moderate to severe thrombocytopenia, anemia, and elevated CRP and ALP values ([Table 1](#t001){ref-type="table"}). All patients had peripheral edema, ascites, pleural effusion, and pericardial effusion. Four patients had peripheral edema as the initial and dominant symptom. All patients had hypoproteinemia. All patients were negative for HHV8, HIV, and Epstein Barr virus. Serum rheumatoid factor and antibodies, including antinuclear, anti-DNA, anti-Sm, anti-RNP antibodies, the perinuclear anti-neutrophil cytoplasmic antibody, and cytoplasmic anti-neutrophil cytoplasmic antibody, were all negative. Three patients (cases 2, 5, and 6) had anti-SS-A and anti-SS-B bodies but no symptoms of Sjögren\'s syndrome. In five patients (cases 1, 2, 3, 4, and 6), the anti-HLA class I antibody was positive. Four patients (cases 1, 2, 3 and 4) had diabetes. CT findings revealed small lymphadenopathy (\<2 cm in diameter), bilateral pleural effusion, ascites, or splenomegaly ([Table 2](#t002){ref-type="table"}, [Fig. 1a and b](#g001){ref-type="fig"}). The lymph node biopsy specimens of four patients (cases 2-5) showed atrophic germinal centers, an expanded interfollicular zone, the proliferation of highly dense endothelial venules, and few plasma cells ([Table 1](#t001){ref-type="table"}, [Fig. 2](#g002){ref-type="fig"}). Bone marrow aspiration and a biopsy were performed on all patients and revealed hypercellular marrow with myelofibrosis or an increased number of megakaryocytes without pathological cells or the dysplastic changes of hemophagocytosis ([Table 2](#t002){ref-type="table"}, [Fig. 3](#g003){ref-type="fig"}).

###### 

Laboratory Results on Admission.

  -------------------------------------------------------------------------------------------------------------------------------
  Patient case\   Sex   Age   WBC\          Hb\        Plt\          CRP\       Cre\        ALP\        IgG\          sIL2R\
  No.                         (×10^9^/L)\   (mg/dL)\   (×10^9^/L)\   (mg/dL)\   (mg/dL)\    (IU/L)\     (mg/dL)\      (U/mL)\
                              (4-7)         (12-16)    (15-40)       (\<0.3)    (0.4-0.8)   (104-338)   (870-1,700)   (145-519)
  --------------- ----- ----- ------------- ---------- ------------- ---------- ----------- ----------- ------------- -----------
  1               M     84    9.4           8.1        2.7           15         2.01        432         1,020         986

  2               M     66    7.2           8.3        1.1           14.65      6.55        611         1,603         1,720

  3               M     79    6.6           7.9        3.2           10.2       3.82        630         1,016         1,150

  4               F     72    14.3          9.6        3.4           7.45       2.32        480         1,200         1,630

  5               F     67    21.3          7.4        2.3           25.5       3.46        650         1,120         1,100

  6               M     78    11.7          9.6        1.8           32.7       2.13        526         1,280         1,849
  -------------------------------------------------------------------------------------------------------------------------------

WBC: white blood cells, Hb: hemoglobin, Plt: platelets, CRP: C-reactive protein, ALP: alkaline phosphatase, IgG: immunoglobulin G, sIL2R: soluble interleukin-2 receptor

###### 

Results of Auto-antibody, CT Findings, Lymph Node Biopsy Findings, and Bone Marrow Aspirate and Trephine Biopsy Findings on Admission.

  Patient case No.   Auto-antibody        CT findings                               Lymph node biopsy findings   Bone marrow aspirate and biopsy findings
  ------------------ -------------------- ----------------------------------------- ---------------------------- --------------------------------------------------
  1                  HLA-Ab               ascites, splenomegaly                     ND                           myelofibrosis, increased level of megakaryocytes
  2                  HLA-Ab, ss-A, ss-B   pleural effusion, ascites, splenomegaly   hyaline-vascular type        myelofibrosis, increased level of megakaryocytes
  3                  HLA-Ab               pleural effusion, ascites, splenomegaly   mixed type                   myelofibrosis
  4                  HLA-Ab               pleural effusion, ascites, splenomegaly   hyaline-vascular type        myelofibrosis, increased level of megakaryocytes
  5                  ss-A, ss-B           pleural effusion, ascites, splenomegaly   hyaline-vascular type        increased level of megakaryocytes
  6                  ss-A, ss-B, HLA-Ab   pleural effusion, ascites, splenomegaly   ND                           increased level of megakaryocytes

CT: computed tomography, HLA-Ab: human leukocyte antigen-antibody, ND: not done

![Computed tomography (CT) on admission and after treatment with thyroxine supplements. (a, b) CT showing bilateral pleural effusion, ascites and splenomegaly. (c, d) CT showing the disappearance of bilateral pleural effusion and ascites.](1349-7235-58-2615-g001){#g001}

![Histological findings of TAFRO syndrome lymph nodes (a, b). (a) A biopsy specimen of a mildly enlarged lymph node showing atrophic centers and intact sinuses (Hematoxylin and Eosin staining, ×20). (b) The marked proliferation of high endothelial venules was observed in germinal centers and interfollicular zones (×40).](1349-7235-58-2615-g002){#g002}

![Histological findings of TAFRO syndrome bone marrow (a, b). (a) A biopsy specimen showing hypercellular marrow (×20). (b) Silver staining showing a very loose network of reticulin fibers (×20).](1349-7235-58-2615-g003){#g003}

The results of the thyroid function study as well as levels of auto-antibodies, serum IL-6, and VEGF are summarized in [Table 3](#t003){ref-type="table"}. Antithyroid peroxidase antibodies and antithyroglobulin antibodies were positive in all cases. Five patients (cases 1-4, 6) had subclinical hypothyroidism, while one (case 5) had clinical hypothyroidism. Common symptoms in these six patients included tiredness, lethargy, and weight gain.

Plasma VEGF levels were elevated in all cases, with a mean level of 256 pg/mL. Serum IL-6 levels were elevated slightly, with a mean level of 14.8 pg/mL ([Table 3](#t003){ref-type="table"}).

###### 

Results of Thyroid Function Study and Serum IL-6 and Plasma VEGF Levels on Admission.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Patient case\   TSH\          FT4\          FT3\          TPOAb\     TGAb\      IL-6\      VEGF\      Symptoms
  No.             (μIU/mL)\     (ng/dL)\      (pg/dL)\      (IU/mL)\   (IU/mL)\   (pg/mL)\   (pg/mL)\   
                  (0.43-4.82)   (0.87-1.72)   (2.39-3.86)   (\<9.4)    (\<54.6)   (\<4)      (\<38.3)   
  --------------- ------------- ------------- ------------- ---------- ---------- ---------- ---------- ----------------------------------
  1               6.23          0.9           2.42          23.4       87         10.2       230        tiredness, weight gain

  2               9.46          0.87          2.2           76.4       260        12.3       323        tiredness, weight gain

  3               6.01          1.24          2.1           19.6       230        24         224        tiredness, lethargy, weight gain

  4               8.82          1.1           1.98          56         705        21.2       250        tiredness, weight gain

  5               8.4           0.6           1.3           34         243        6.5        249        tiredness, weight gain

  6               9.3           0.93          0.4           42         112        6.3        262        tiredness, weight gain
  ----------------------------------------------------------------------------------------------------------------------------------------

TSH: thyroid stimulatingthyroid-stimulating hormone, FT4: free T4, FT3: free T3, TPOAb: antithyroid peroxidase antibody, TGAb: antithyroglobulin antibody, IL-6: interleukin-6, VEGF: vascular endothelial growth factor

As shown in [Table 4](#t004){ref-type="table"}, All patients were treated with glucocorticoids. In cases 1 and 3, thrombocytopenia and renal dysfunction improved, whereas peripheral edema, ascites, and pleural effusion remained and relapsed with VEGF and TSH elevation. Case 2 died of sepsis three months after the disease onset. Three patients (cases 4, 5, and 6) received thyroxine supplement treatment. A dose of 100-150 μg/day was effective in these patients. Following the administration of thyroxine supplements at the same time as combination immunotherapy or chemotherapy, edema, effusion, thrombocytopenia, the results of renal and thyroid function tests and plasma VEGF levels improved ([Table 4](#t004){ref-type="table"}, [Fig. 1c and d](#g001){ref-type="fig"}). The condition of these three patients has since remained stable with no further evidence of TAFRO syndrome.

###### 

Treatments and Outcomes of Patients.

  Patient case No.   Treatment                        Thyroxine supplement   Laboratory data after the treatment   Outcome                                                   
  ------------------ -------------------------------- ---------------------- ------------------------------------- --------- ------ ------ ------ ----- ------ ------ ------ ----------------------------------
  1                  mPSL, PSL                        ND                     7.5                                   10.2      6.3    0.3    0.76   230   7.23   0.86   240    died at 20 months due to relapse
  2                  mPSL, PSL                        ND                     5.6                                   9         4.2    1.4    2.45   520   10.4   0.76   280    died at 3 months due to sepsis
  3                  mPSL, rituximab                  ND                     3.8                                   9.4       8.4    0.62   1.32   420   8.6    0.88   226    died at 40 months due to relapse
  4                  mPSL, CyA, R-CHOP, toralizumab   100 μg/day             6.5                                   11.2      15.3   0.31   0.89   246   2.79   1.02   10.2   improved and alive at 46 months
  5                  mPSL, CyA                        150 μg/day             3.4                                   10.6      14.2   0.42   1.1    302   2.79   1.6    22     improved and alive at 10 months
  6                  mPSL, CHOP                       150 μg/day             3.2                                   10.3      8.7    1.3    1.3    335   1.63   0.93   16     improved and alive at 4 months

WBC: white blood cells, Hb: hemoglobin, Plt: platelets, CRP: C-reactive protein, Cre: creatinine, ALP: alkaline phosphatase, TSH: thyroid stimulatingthyroid-stimulating hormone, FT4: free T4, VEGF: vascular endothelial growth factor, mPSL: methylprednisolone, PSL: prednisolone, CyA: ciclosporin, ND: not done

Discussion
==========

This study extends our previous study of TAFRO syndrome ([@B7]). To our knowledge, this is the first study that demonstrates the relationship between subclinical hypothyroidism and TAFRO syndrome with VEGF elevation.

VEGF induces a rapid and reversible increase in vascular permeability, which may induce the development of clinical manifestations, such as ascites, pleural effusion, peripheral edema, and organomegaly. A relationship between edema and increased VEGF levels was recently reported for POEMS syndrome, which often accompanies an extravascular volume overload ([@B4], [@B5]). VEGF is expressed in a number of normal adult tissues, including the kidneys, lungs, uterus, ovary, brain, heart, skin, pituitary gland, and macrophages. It has been demonstrated *in vitro* that VEGF is produced by thyroid follicular epithelial cells in response to the stimulation of the TSH receptor ([@B8]). Secreted VEGF was shown to stimulate VEGF receptors on the endothelial cells of thiouracil-fed rats via a TSH-dependent paracrine mechanism, leading to the proliferation of endothelial cells and hypervascularity of the thyroid gland. Klein et al. reported that recombinant human TSH stimulation for three weeks induced local VEGF expression in normal human thyroid grafted into nude mice ([@B9]). Iitaka et al. showed that serum VEGF levels positively correlated with TSH levels in patients with Hashimoto\'s thyroiditis ([@B10]). Furthermore, Sorvillo et al. suggested that TSH *in vivo* may regulate the VEGF production from extrathyroidal tissues ([@B11]). One possible explanation for this is that VEGF levels may be increased by the prolonged stimulation of TSH. Secreted VEGF may then stimulate VEGF receptors on endothelial cells, leading to an increase in vascular permeability and the development of TAFRO syndrome. In general, previous reports have suggested that levothyroxine treatment is unlikely to reduce symptoms in people with modest elevations in TSH levels and minimal symptoms at baseline, but such a treatment may have benefit in symptomatic patients, particularly in those who have high TSH levels ([@B12]-[@B14]). However, levothyroxine treatment may be beneficial for subclinical hypothyroidism with modest elevations in TSH levels in TAFRO syndrome, such as in the present cases.

In Castleman disease, hypothyroidism is the most common endocrine manifestation, being observed in 58% patients ([@B15]). Yu et al. reported that 39% of iMCD patients had a history of autoimmune diseases, which were typically stable at the time of the diagnosis ([@B16]). Furthermore, they showed that treatments resulted in the improvement or resolution of both iMCD and the signs and symptoms of autoimmune connective tissue diseases. Based on the overlap between iMCD and autoimmune diseases, autoimmunity may be responsible for initiating or perpetuating the cytokine storm in iMCD via an autoantibody antigenic stimulation. There is only one report describing the clinical significance of hypothyroidism in TAFRO syndrome ([@B7]), and subclinical hypothyroidism with the presence of autoantibodies suggests that autoimmunity is a pathological cause of TAFRO syndrome.

Although the clinical significance of hypothyroidism in TAFRO syndrome is unknown, VEGF levels decreased with improvements in the condition of three refractory cases after thyroid hormone replacement therapy in the present study. A possible explanation for this is that VEGF levels may be increased by the prolonged stimulation of TSH. Secreted VEGF may then stimulate VEGF receptors on endothelial cells, leading to an increase in vascular permeability and the development of TAFRO syndrome. Subclinical hypothyroidism may be one of the causes, although confirming this will require further investigations.

Various treatments (corticosteroids, cyclosporin, rituximab, cytotoxic lymphoma-based chemotherapies, tocilizumab, siltuximab, bortezomib, thalidomide, and anakinra) have been used for patients with iMCD ([@B5], [@B17], [@B18]); however, relapse is common, and standard protocols have not yet been established ([@B1]). The pathogenesis of iMCD and TAFRO syndrome need to be elucidated in more detail in order to provide additional candidate targeted therapies.

The underlying mechanisms of and standard therapeutic strategies for TAFRO syndrome have yet to be established. Our results indicate that even biochemical subclinical hypothyroidism causes severe clinical manifestations, which prompted us to speculate that elevated VEGF levels are a potential factor in the pathogenesis and symptomatology of TAFRO syndrome with subclinical hypothyroidism. Further studies are needed to clarify its prognosis, pathophysiology, and appropriate treatments.
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